Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SENNA+CASSIA · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| SENNA + CASSIA (Naturetti) | EXPERIMENTAL | Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days |
| SENNA+ CASSIA | EXPERIMENTAL | Daily administration (capsule) of Naturetti (SENNA+ CASSIA) at bedtime, during 30 days |
| Placebo | PLACEBO_COMPARATOR | Daily administration (capsule) of placebo at bedtime, during 30 days |
| Name | Type | Description |
|---|---|---|
| SENNA+CASSIA(Naturetti) | DRUG | Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days |
| SENNA+CASSIA | DRUG | Pharmaceutical form: capsule Route of administration: oral Dose regimen: once a day |
| placebo | DRUG | Pharmaceutical form: Capsule Route of administration: oral Dose regimen: once a day |
Inclusion criteria: * Having chronic functional constipation by ROME IIII criteria * Having the majority of the stool as type 1 or 2 by Bristol Stool Scale * Female subjects should be using an effective contraceptive method more than 3 months if they are sexually active and on reproductive stage * ...
SENNA+CASSIA is used for the treatment of constipation. It is a small molecule combination product developed by Sanofi for the gastrointestinal therapeutic area. The clinical program has focused on chronic functional constipation, with two completed Phase 3 trials conducted in Brazil.
SENNA+CASSIA is developed by Sanofi, which trades under the ticker SNY. Sanofi is the sponsor of the clinical program for this constipation treatment.
SENNA+CASSIA is in Phase 3 development. Two Phase 3 trials have been completed, and there are currently no active trials listed for this asset. The completed studies enrolled a total of 213 participants.
SENNA+CASSIA has been evaluated in two completed Phase 3 trials: NCT00994851, which studied Cassia Fistula plus Senna Alexandrina Miller in chronic functional constipation and enrolled 96 participants, and NCT00931853, which assessed a sugar-free formulation in the same condition and enrolled 117 participants. Both trials were conducted in Brazil.